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Objective: To identify novel causes of recessive ataxias, including spinocerebellar ataxia with saccadic intrusions,
spastic ataxias, and spastic paraplegia.
Methods: In an international collaboration, we independently performed exome sequencing in 7 families with reces-
sive ataxia and/or spastic paraplegia. To evaluate the role of VPS13D mutations, we evaluated a Drosophila knockout
model and investigated mitochondrial function in patient-derived fibroblast cultures.
Results: Exome sequencing identified compound heterozygous mutations in VPS13D on chromosome 1p36 in all 7 fami-
lies. This included a large family with 5 affected siblings with spinocerebellar ataxia with saccadic intrusions (SCASI), or spi-
nocerebellar ataxia, recessive, type 4 (SCAR4). Linkage to chromosome 1p36 was found in this family with a logarithm of
odds score of 3.1. The phenotypic spectrum in our 12 patients was broad. Although most presented with ataxia, addi-
tional or predominant spasticity was present in 5 patients. Disease onset ranged from infancy to 39 years, and symptoms
were slowly progressive and included loss of independent ambulation in 5. All but 2 patients carried a loss-of-function
(nonsense or splice site) mutation on one and a missense mutation on the other allele. Knockdown or removal of Vps13D
in Drosophila neurons led to changes in mitochondrial morphology and impairment in mitochondrial distribution along
axons. Patient fibroblasts showed altered morphology and functionality including reduced energy production.
Interpretation: Our study demonstrates that compound heterozygous mutations in VPS13D cause movement disorders
along the ataxia–spasticity spectrum, making VPS13D the fourth VPS13 paralog involved in neurological disorders.
ANN NEUROL 2018;00:000–000
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.25220
Received Nov 1, 2017, and in revised form Mar 11, 2018. Accepted for publication Mar 19, 2018.
Address correspondence to Dr Burmeister, Molecular and Behavioral Neuroscience Institute, University of Michigan, 5061 BSRB, 109 Zina Pitcher Place,
Ann Arbor, MI 48109-2200, E-mail: margit@umich.edu; Dr van de Warrenburg, Department of Neurology 935, Donders Institute for Brain, Cognition,
and Behavior, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, the Netherlands, E-mail: Bart.vandeWarrenburg@radboudumc.nl;
and Dr Lohmann, Institute of Neurogenetics, University of L€ubeck, Maria-Goeppert-Straße 1, 23562 L€ubeck, Germany; E-mail: katja.lohmann@neuro.uni-
luebeck.de
From the 1Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI; 2Department of Molecular, Cellular, and
Developmental Biology, University of Michigan, Ann Arbor, MI; 3Institute of Neurogenetics, University of L€ubeck, L€ubeck, Germany; 4Department of
Human Genetics, Radboud University Medical Centre, Nijmegen, the Netherlands; 5Department of Neurology, University of L€ubeck, L€ubeck, Germany;
6Department of Human Genetics, University of Michigan, Ann Arbor, MI; 7Department of Computational Medicine and Bioinformatics, University of
Michigan, Ann Arbor, MI; 8Department of Pediatrics, Section on Medical Genetics, Wake Forest School of Medicine, Winston-Salem, NC; 9Department
of Clinical Genetics, Erasmus MC, Rotterdam, the Netherlands; 10Departments of Neurology and Molecular and Integrative Physiology, University of
Michigan, Ann Arbor, MI; 11Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Centre,
Nijmegen, the Netherlands; and 12Department of Psychiatry, University of Michigan, Ann Arbor, MI
Current address for Sheng Li: Bio-X Center, Shanghai Jiao Tong University, China
VC 2018 American Neurological Association 1
Ataxia is a symptom of >400 syndromic neurologicalconditions or can be the sole symptom of >80 reces-
sively, dominantly, or X-linked inherited genetically defined
conditions.1–3 Recessive forms of ataxia are clinically and
genetically more heterogeneous than dominant ataxias.
Only in a minor fraction (20%) of idiopathic or suspected
recessive ataxia cases can a mutation in a known ataxia gene
be identified,4 suggesting that much of the genetic heteroge-
neity still remains to be discovered. In addition to heteroge-
neity, there is also pleiotropy, as the spectrum of ataxias also
includes clinical and molecular overlap with, for example,
the spastic paraplegias.5
Here, we report 12 patients from 7 families with
compound heterozygous mutations in VPS13D. All pa-
tients> 2 years old have ataxia and/or spasticity, whereas
the one 2-year-old patient shows developmental delay
and hypotonia and is nonambulatory (see Supplementary
Table). The phenotype in 1 of these families, comprising
5 patients (Fig 1), has previously been described in
detail.6,7 Briefly, patients in this family demonstrated
early adult onset cerebellar ataxia with neuropathy and
pyramidal signs, as well as striking saccadic intrusions,
hence initially referred to as spinocerebellar ataxia with
saccadic intrusion (SCASI),6 later renamed spinocerebel-
lar ataxia, recessive, type 4 (SCAR4). Analysis of Drosoph-
ila knockout models and patient-derived fibroblasts
suggests that mutations in this new ataxia/spasticity gene
impact on mitochondrial structure and function.
Materials and Methods
Patients
Patients were identified in 5 different centers with a focus on
movement disorders located at Case Western Reserve University
(Cleveland, OH) and genetically analyzed in Ann Arbor (MI,
UM1), Nijmegen and Rotterdam (the Netherlands, NIJ1–4),
L€ubeck (Germany, LUB1), and Winston-Salem (NC, USA,
WF1). Diagnostic testing (including gene panel analysis of
known ataxia/spasticity genes) did not reveal a molecular diag-
nosis in these cases. All patients and relatives gave written
informed consent to participate in diagnostic or research studies
that were approved by the respective local institutional review
boards (Institutional Review Boards of the University of Michi-
gan Medical School, University of L€ubeck ethics review panel),
or to local (NIJ and Rotterdam) or commercial (WF1; Gen-
eDx, Gaithersburg, MD) clinical exome sequencing (NIJ and
WF1). Formation of this collaboration was facilitated by publi-
cation of grants funded by the National Ataxia Foundation and
by GeneMatcher.8
Genetic Studies: Linkage Analysis
and Exome Sequencing
In Family UM1, linkage analysis was performed with DNA
from all 5 affected members, the mother, and 7 unaffected
siblings using the Infinium HumanLinkage-24 Beadchip kit
(6,000 markers, WG-32-140; Illumina, San Diego, CA), fol-
lowed by parametric fully penetrant recessive model analysis in
Merlin.9
In all families, whole exome sequencing was performed
by exome capture (UM1: SeqCap EZ Exome Kit v3.0 [Roche
Sequencing, Pleasanton, CA] at UM core facility; LUB1: Nex-
teraRapid Exome Capture Kit [Illumina] at Centogene [Ros-
tock, Germany]; all NIJ cases and WF1: SureSelectXT Human
All Exon 50Mb Kit V5 [Agilent Technologies, Santa Clara,
CA] at BGI Copenhagen [NIJ] and at GeneDx [WF1]) fol-
lowed by next generation sequencing on Illumina arrays (UM1
and LUB1: paired end HiSeq2000; LUB1: NextSeq500) to
medium coverage of 463 (UM1) or to 753 (all NIJ, LUB1,
and WF1).
For UM1, 2 cases were sequenced and variant analysis was
restricted to the 10Mb linkage region. For LUB1, WF1, and
NIJ4, parents were also sequenced and initially, a trio analysis for
de novo variants (no damaging hits) was performed. Variants
were called as follows. For UM1.1 and UM1.4, alignment was
done using Burrows-Wheeler Aligner against Human 1K
Genome reference, duplicates were removed using Picard (v1.74),
base recalibration, realignment, and variant calling were done
using GATK (v3.3); these samples were part of a 734-sample
pooled call. For LUB1, variant calling was performed as
described.10 For NIJ, clinical exome sequencing and variant call-
ing were performed as described.11 For WF1, GeneDx clinical
whole exome pipeline was employed. Detected variants were fil-
tered for rare (European population frequency< 0.01) and
protein-changing variants under a recessive model. VPS13D var-
iants emerged as the strongest candidate in all cases.
All VPS13D variants were Sanger confirmed and segrega-
tion in the family consistent with compound heterozygosity was
verified.
Copy number variant analysis was not performed on all
samples. Because single exonic deletions are difficult to detect
in whole exome analyses, they cannot be ruled out. Because all
patients were compound heterozygous, a whole gene deletion in
VPS13D can be ruled out.
Analysis of Expression: Nonsense-Mediated
Decay and Splice Site Prediction
Because VPS13D expression is higher in skin (fibroblasts) than
in blood, we used mRNA extracted from a fibroblast culture to
study expression levels and nonsense-mediated mRNA decay
(NMD) in Family UM1 (data not shown) and Patient LUB1.1.
For Patient LUB1.1, RNA was extracted using the QIAmp
RNA Extraction Kit (Qiagen, Germantown, MD). Oligo-dT-
nucleotides of the Maxima First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific, Waltham, MA) served as primers to
synthesize the complementary DNA (cDNA) by use of reverse
transcriptase (RT). Polymerase chain reaction (PCR) was per-
formed with primers in exons 21 and 22 (VPS13Dex21F:
TGATTCCTTAGTCCA CATCAAC; VPS13Dex22R:
ATCATTTCCAGGTGTGC TAC), and the respective product
was inspected for its size and Sanger sequenced. Furthermore,
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the expression of VPS13D in LUB1.1 and a control was com-
pared to the expression of ß -actin, HPRT, and YAZ, which
served as reference genes. These quantitative PCRs were per-
formed with SYBR Green on the LightCycler 480 system
(Roche Molecular Systems; data not shown). Because both
quantitative PCR and sequencing indicated instability of the
allele with the nonsense mutation, we treated fibroblasts of
LUB1.1 with cycloheximide for 8 hours at 100 lg/ml final con-
centration to stabilize the transcript and confirm -NMD- as the
cause. The effect of cycloheximide was evaluated by sequencing
of cDNA.
In addition to nonsense and missense mutations, we
detected 3 variants at splice sites (c.9411 3A>G, c.2237-
1G>C, c.99981 4A>C). Because we are limited in performing
skin biopsy for research purposes to adults only, per our institu-
tional review board, we do not have fibroblast cultures from
the children with splice mutations. Instead, we used 2 online
slice site prediction tools to estimate the impact of these var-
iants on splicing: Human Splicing Finder (HSF; http://www.
umd.be/HSF3/) 12 and Splice Site Prediction (SSP; http://www.
fruitfly.org/seq_tools/splice.html), set to mammals. HSF
provides a consensus value (CV) variation as output with the
interpretation of CV<210% indicating a disruption of the
splice site. SSP generates a score between 0 and 1, with a score
of 0.5 recognizing about 90% of the actual sites and a false-
positive rate of< 5%. The higher the score, the higher the
probability that the splice site is active.
Comparison of Mutation Frequencies
in VPS13D Paralogs
To assess the impact of the loss of function of each VPS13
paralogs, we compared phenotypes of animal models available
in the literature and in databases and examined estimates of
mutation frequencies in humans. To assess the common muta-
tion types (eg, loss of function, missense) in each VPS13
paralog-associated disease, we restricted analysis to cases in
which both mutations are known.
Functional Studies in Patient-Derived
Fibroblasts
From the UM1 family, we established fibroblast cell lines from 2
patients (UM1.2 and UM1.4) and 2 controls (UM1.17, a
FIGURE 1: Multiplex ataxia families with compound heterozygous mutations in VPS13D. (A) Pedigree of Family UM1. Affected
siblings are indicated by black filled symbols; unaffected individuals are marked by unfilled symbols. The 9 unaffected siblings
are shown with an open diamond. Mutational status is given below each individual together with the respective laboratory ID.
(B) Pedigree of Family LUB1 with mutations in the 2 affected sisters, shown by black filled symbols. (C) cDNA sequences of the
c.5409C>A mutation before (top panel) and after (lower panel) treatment with cycloheximide (CHX). The traces are representa-
tive of 2 sequencing runs. The nonsense-mutated allele was stabilized and showed similar expression levels upon treatment.
(D) Predicted domain maps of VPS13D protein (http://www.ebi.ac.uk/interpro/protein/Q5THJ4) with the identified missense
mutations marked: N15VPS13 1st N-terminal domain (amino acids [aa] 2–115); N25VPS13 2nd N-terminal domain (aa 137–
356); RPT5Repeated Coil Region; U5UBA (ubiquitin-associated)-like domain (aa 2627–2679); SHR5VPS13 short root tran-
scription factor-binding domain (aa 3276–3558); C5VPS13 C-terminal domain (aa 3983–4129). The 5 different missense muta-
tions appear to cluster in 2 regions, one in the middle and the other near the C domain. (E) Amino acid sequence alignments
of the regions surrounding each missense mutation across various species. Whereas Gly1190Asp, Asn4107Ile, and Gly4149Ser
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daughter of an affected, and UMCtrl1, a married-in unaffected
spouse). From LUB1, fibroblast lines were established from
LUB1.1, the index patient, and her heterozygous parents (LUB1.3
and LUB1.4). In addition, fibroblasts from 2 unrelated control
lines (LUBCtrl1, also known as L-2132; LUBCtrl2, also known as
L-2134) were used.
For mitochondrial imaging in fibroblast from the UM1
family, MitoTracker Red CMXRos (Invitrogen, Carlsbad, CA)
was applied to fibroblasts cultured on coverslips for 40 minutes
before fixing in 4% formaldehyde for 12 minutes. Through a
PLAPON 603 (1.42 Oil) lens on an Olympus (Tokyo, Japan)
FV1000 confocal microscope, 6 to 8 Z stacks of images were
obtained per visual field to produce images of in total approxi-
mately 72 to 127 cells per line. Images were flattened using Z-
projection at maximum intensity using the open software Fiji,13
which was also used to generate intensity histograms. For each
2-dimensional image, the Otsu algorithm was applied to extract
the top 1% brightest pixels. To quantify spherical mitochon-
dria, any areas smaller than 1.5 mm2 and with less circularity
than 0.18 were removed using Fiji’s Analyze Particles function.
The remaining selected areas correspond to bright and spherical
mitochondria. The average number of such selected objects per
cell was calculated in each cell line. We also computed the per-
centage of cells with >2 such objects in the perinuclear region.
Form factor analysis as a measurement of the mitochondrial
network integrity was performed by using a selection algorithm
in the software program Volocity (PerkinElmer, Waltham, MA)
to select mitochondrial objects (1 standard deviation above the
mean MitoTracker intensity) of a projected z stack image (aver-
age intensity). For each projected image containing 4 to 12
cells, form factor, defined as ½P2m=½4pAm with Pm being the
perimeter and Am being the area of a mitochondrion, was cal-
culated for all selected mitochondria, and the mean was
obtained for the entire image field. For each individual, 11 to
17 images from 2 independent experiments were analyzed.
In fibroblasts of Family LUB1, the form factor was deter-
mined as previously described.14 In brief, the mitochondrial
network in fibroblasts was stained with an anti-GRP75 anti-
body (1:1,000; Abcam, Cambridge, MA) in combination with
the Zenon immunolabelling kit (Invitrogen) according to the
manufacturer’s protocol. Based on single cell images, mitochon-
dria area and outline were measured and the form factor was
calculated. Mean form factor was averaged over 20 cells per
individual.
Measurement of the Rate of Adenosine
Triphosphate Synthesis in Cultured Fibroblasts
Adenosine triphosphate (ATP) was quantified, in triplicate, using
the ATP Bioluminiscence Assay Kit CLS II (Roche Diagnostics,
Mannheim, Germany) following the manufacturer’s instructions.
ATP was measured in a luminometer (Berthold Detection Systems,
Pforzheim, Germany), and calculated as ATP generated (micro-
moles) per minute per milligram of protein. The amount of pro-
tein was determined using the BCA Protein Assay Kit (Pierce,
Rockford, IL).
Functional Studies in Drosophila Models
All fly lines and related constructs were purchased from the
Bloomington Stock Center (Bloomington, IN), including
Vps13D mutant lines (#56282 [Vps13D11101] and #22996;
only #56282 homozygous shown), Vps13D RNA interference
(RNAi; #38320), motoneuron-specific Gal4 driver (D42-Gal4,
#8816), a deficiency line Df(3L)Exel6117 (#7596), and fluores-
cent mitochondrial marker (UAS-mitoGFP, #42727).15 All phe-
notypes observed of homozygous Vps13D mutant alleles were
confirmed in compound heterozygous flies of the 2 alleles, and
in mutant alleles over the deficiency line, which lacks a defined
region of the Drosophila chromosome containing the entire
Vps13D genetic locus and some neighboring genes. For stain-
ing, we used the following primary antibodies: ATP5A (Abcam
ab14748), green fluorescent protein (GFP; Life Technologies,
Carlsbad, CA; A-11122, 1:1,000), horseradish peroxidase (Jack-
son ImmunoResearch, West Grove, PA; 123-605-021, 1:1,000),
and discs large (Dlg1) (Developmental Studies Hybridoma
Bank, Iowa City, IA; 4f3, 1:1,000). All secondary antibodies
were from Invitrogen (Alexa-conjugated 1:1,000, 2 hours, RT).
Standard dissection and immunostaining procedures were used
for larval tissue analysis.16 For larval immunostaining, tissues
were fixed with 4% formaldehyde for 20 minutes at room tem-
perature prior to staining, except for anti-ATP5A staining, in
which tissue was fixed with Bouin fixative for 7 minutes at
room temperature. Form factor analysis of larval ventral nerve
cords was performed using Volocity to select mitochondrial net-
works in the cell bodies of RNAi expressing motoneurons based
on threshold of mitoGFP fluorescence (2.5 standard deviations
above the mean fluorescence intensity) from a projected z stack
image. For each cell body, an average form factor of all mito-
chondria was calculated.
Statistical Analyses
Differences were analyzed statistically using unpaired t tests, or
analysis of variance with a Bonferroni–Dunn post hoc correction.
Results
Genetic Findings
OVERVIEW. In 4 different locations in the USA and
Europe, we independently detected compound heterozy-
gous VPS13Dmutations in 7 families. The mutational spec-
trum included 5 nonsense, 5 missense, 1 frameshift, 1
essential, and 2 nonessential splice site mutations (Table 1).
All families carried a combination of 1 loss-of-function
(LOF) mutation (nonsense, frameshift, or essential splice
sites) and 1 presumably milder change (missense or nones-
sential splice site mutation). All variants were absent or
extremely rare (<13 heterozygous carriers) in the 120,000
individuals listed in gnomAD. Among the 5 missense muta-
tions, Gly1190Asp and Met1307Ile, found in families
UM1 and NIJ1, were located in the center of the protein.
The three C-terminal missense mutations detected in fami-
lies LUB1, NIJ2, and NIJ3 are close to or within the C-
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domain (see Fig 1D), which is conserved and unique among
all VPS13 proteins including yeast.
UM1 ATAXIA FAMILY (SCAR4). We have previously
reported a family with 14 siblings, 5 of whom had adult
onset spinocerebellar ataxia with saccadic eye intrusion (see
Fig 1A; SCAR46,7. After exclusion of known ataxia muta-
tions, genome-wide linkage analysis under a recessive, full
penetrance model identified only a single locus with loga-
rithm of odds (LOD)> 0, which was 20cM/ 10Mb on
chromosome 1p36 flanked by rs7538691 and rs761162
(LOD5 3.1, data not shown). Whole exome sequencing in
2 affected individuals revealed compound heterozygous
mutations in VPS13D as the only likely genetic cause within
the linked region. The variants comprised a paternally
inherited missense change (c.3569G>A, p.Gly1190Asp)
and a maternally inherited nonsense mutation (c.3316C>
T, p.Gln1106Ter). Sanger sequencing verified segregation
among all 12 siblings with available DNA samples.
Sequencing of RT-PCR products from fibroblast cell lines
of 2 patients demonstrated that the nonsense allele-contain-
ing mRNA product was less abundant, suggesting that it
TABLE 1. Compound Heterozygous VPS13D Mutations Identified in Each Ataxia/Spasticity Family
Subject Mutation
Protein
NP_056193
Mutation
cDNA
NM_015378
Mutation
Genomic
Level
CADD
Score
Mutation
Taster
Frequency,
gnomAD
Human
Splicing
Finder
Splice Site
Prediction
UM1
Gly1190Asp 3569G>A chr1:12337214G>A 25 Disease
causing
Not reported
Gln1106Ter 3316C>T chr1:12336961C>T 39 Disease
causing
Not reported
LUB1
Ala4210Val 12629C>T chr1:12520418C>T 34 Disease
causing
0.00004039
Tyr1803Ter 5409C>A chr1:12343568C>A 33 Disease
causing
Not reported
NIJ1
Met1307Leu 3919A>T chr1:12337564A>T 19 Disease
causing
0.00004885
Gln662Ter 1984C>T chr1:12331062C>T 40 Disease
causing
Not reported
NIJ2
Gly4149Ser 12445G>A chr1:12516165G>A 35 Disease
causing
Not reported
Gln2572Ter 7714C>T chr1:12382602C>T 51 Disease
causing
Not reported
NIJ3
Splicing ? 9411 3A>G chr1:12317147A>G 17 NA Not reported 20.83% 0.89!0.21
Val2987Gly
fsX14
8960_8961
delTG
chr1:12405505delTG 35 Disease
causing
Not reported
NIJ4
Asn4107Ile 12320A>T chr1:12476867A>T 30 Disease
causing
Not reported
Splicing
(essential)
2237-1G>C chr1:12335881G>C 23 NA Not reported 231.07% 0.99!0.00
WF1
Splicing ? 99981 4A>C chr1:12416585A>C 9.6 NA 0.00003738 210.57% 0.93!0.62
Leu2277Ter 6829delC chr1:12371876delC 35 Disease
causing
Not reported
Coordinates of all detected mutations are based on NM_015378 for cDNA and GRCH37/hg19 built for genomic DNA. CADD score and Muta-
tionTaster are in silico prediction of deleteriousness of each mutation. Three of the mutations have been reported previously in public exome/
genome databases (gnomAD: genome aggregation consortium at http://gnomad.broadinstitute.org/gene/ENSG00000048707). For splice variants,
splice site prediction scores were calculated at Human Splicing Finder (http://www.umd.be/HSF3/) and Splice Site Prediction (http://www.fruitfly.
org/seq_tools/splice.html).
CADD5Combined Annotation Dependent Depletion; NA5 no assessment.
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underwent NMD (data not shown). Gly1190Asp
introduces an extra negative charge and appears not to affect
protein stability (data not shown).
FAMILY LUB1. In 2 affected sisters of a German family
with spastic ataxia (see Fig 1B), we detected compound
heterozygous mutations in VPS13D including a maternal
nonsense mutation (Tyr1803Ter) and a paternal missense
change (Ala4210Val, rs746736545). Similar to Family
UM1, sequencing of cDNA of the index patient revealed
the allele with the nonsense mutation to be less abun-
dant. Treatment with cycloheximide stabilized the
mutated allele and confirmed that the nonsense-mutated
allele underwent NMD (see Fig 1C). NMD resulted in a
decreased expression level of about 50 to 60% in Patient
LUB1.1 (data not shown).
ADDITIONAL SPORADIC CASES. At the Radboudumc
Expert Centre for genetic movement disorders in Nijmegen,
and the genetic movement clinic in Rotterdam, the Nether-
lands, 4 unrelated cases of different ethnicities with com-
pound heterozygous VPS13D mutations were
independently identified (see Supplementary Table). NIJ1
and NIJ2 carry a combination of a nonsense mutation and
a missense change, NIJ3 carries a frameshift and a nonessen-
tial splice site mutation, and NIJ4 carries an essential splice
site mutation and a missense change. NIJ4 also has optic
atrophy and carries a heterozygous frameshift mutation in
OPA1 (c.1156_1157del [p.Leu386Glufs*2]). A second
(biallelic) mutation in OPA1 was excluded by exome
sequencing with sufficient coverage of the entire coding
region and splice sites. Her mother carried the same variant
and has isolated optic atrophy.
FIGURE 2.
FIGURE 2: Disruption of Vps13D in the Drosophila central
nervous system affects mitochondrial morphology. (A) Ven-
tral nerve cord, stained for mitochondrial marker ATP5A, of
control (w1118, right panel) and Vps13D mutant
(Vps13D11101/11101, left panel) Drosophila larvae. Bottom:
High-magnification single confocal z planes of areas indi-
cated by the dashed boxes, highlighting mitochondrial mor-
phology in neuronal cell bodies. Scale bars: 50mm (top) and
5mm (bottom). (B) Representative images of motoneurons
(via D42-Gal4) with simultaneous expression of fluorescent
mitochondrial marker mitoGFP (green) along with control
(left panel) and Vps13D (right panel) RNAi expression. Bot-
tom: High-magnification single confocal z planes of areas
indicated by the dashed boxes, highlighting mitochondrial
morphology in motoneuron cell bodies. (C) Quantification of
form factor analysis of the mitochondrial network (based on
mitoGFP) in neuronal cells bodies expressing control RNAi
(white) versus Vps13D RNAi (gray); n550 neurons per con-
dition (from 5 different animals). Error bars represent stan-
dard error; ***p<0.001 (Student t test). WT5wild type.
[Color figure can be viewed at www.annalsofneurology.org]
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At the Wake Forest School of Medicine, Winston-
Salem, North Carolina, 1 additional case, WF1, was
identified by clinical exome sequencing (GeneDx). WF1
displayed hypotonia, balance and coordination difficul-
ties, and global developmental delay; more formal clinical
ataxia tests were difficult to perform, due to her current
age and disease features as well as global developmental
delay. WF1 has a combination of a nonsense mutation
and a nonessential splice site change.
To estimate the impact of the splice site changes on
the transcript, we used 2 different in silico splice site predic-
tion programs. As expected, both programs, HSF and SSP,
strongly predicted an effect on splicing of the variant at the
invariant acceptor splice site of intron 18 in NIJ4, c.2237-
1G>C (see Table 1), which hence was classified as LOF.
The splice region variants in NIJ3 and WF1, however, are
not within invariant splice consensus sites. For
c.99981 4>C in intron 49, CV variation was 210.57%,
just below HSF’s 210 cutoff. SSP’s prediction score
dropped from 0.93 to 0.62, suggesting a mild, if any,
impact on recognition of this splice site. For c.9411 3A>G
in intron 9, the CV variation was 20.83% by the HSF
algorithm and would argue against an effect on splicing.
However, the SSP score dropped from 0.89 to 0.21, sugges-
ting reduction in predicted splicing ability. These 2 nones-
sential splice site mutations are hence not considered
complete LOF alleles, as they may allow some correctly
spliced transcripts. Confirmatory analysis of intronic splice
region variants could not be performed at this time (see
Materials and Methods for details).
Clinical Findings
All cases except for WF1, which was too young, had
either ataxia or spasticity as a core symptom. Onset
ranged from infancy to adulthood. The UM1 family,
previously designated as SCAR4, demonstrated primarily
adult onset ataxia with distinct macrosaccadic intrusions,7
with pyramidal features, neuropathy, and myoclonus but
no intellectual disability.6 Videos of the clinical examina-
tions and the distinct eye phenotype are available in the
online supplement of Swartz et al.7 The 2 sisters from
Family LUB1 were similar to UM1 in their onset and
clinical phenotypes, except for a different oculomotor
phenotype. By contrast, NIJ1 had a much earlier onset
(<5 years) and symptoms were more debilitating (wheel-
chair-bound by age 17 years). Whether his phenotypic
difference originates from more severe VPS13D muta-
tions or other environmental or genetic factors is
unknown at this time. Similarly, NIJ4 and WF1 were
severely affected with an age at onset in the first year of
life. In addition to ataxia and neuropathy, NIJ4 suffers
from developmental delay, seizures, and optic atrophy.
Coincidentally, she carries an additional mutation in
OPA1 (optic atrophy 1/ mitochondrial dynamin-like
GTPase), which explains the optic atrophy but not the
additional seizures and the developmental delay. NIJ2
was affected by spastic paraplegia without ataxia, with
onset in early adulthood. Patients WF1 and NIJ3 might
be more severely affected due to 2 severe mutations
including a nonessential splice site change and an LOF
mutation, in contrast to the combination of a missense
and an LOF mutation in the other subjects.
Among VPS13 Paralogs, VPS13D Is the Most
Intolerant to Mutations
Yeast vps13 is implicated in many cellular functions
including sporulation, Golgi organization, and mitochon-
drial integrity.17 During metazoan evolution, 2 duplica-
tion events gave rise to 3 paralogs: VPS13A/C, B, and D.
Drosophila Vps13 (CG2093) is an ortholog of VPS13A/
C, which further duplicated in the vertebrate evolution
into VPS13A and VPS13C (updated from Velayos-Baeza
et al18). Because not much is known about VPS13D-spe-
cific function, we compared reported phenotypes of
VPS13 homologs in the 2 model organisms fly and
mouse (fly: CG209319; mouse: MGI2444304,20
MGI2444207, and MGI2448530; Table 2). Mutations
in Vps13D/VPS13D cause embryonic lethality in both
animals, whereas mutations in VPS13A and C appear
more tolerable during early development (animal pheno-
types for VPS13B are unavailable).
A similar trend was observed in human populations
(see Table 2). Residual Variation Intolerance Score (RVIS)
is a gene-based intolerance score derived from allele fre-
quency in whole exome sequence data.21 Among the
paralogs, VPS13D has the lowest RVIS score of 24.23,
0.14 percentile, suggesting that VPS13D is among the
most mutation-intolerant of human genes. We also com-
pared the frequency of LOF in each paralog in the Exome
Aggregation Consortium (ExAC) browser. Again, VPS13D
emerges as most sensitive to LOF mutations, with the
lowest ratio of the number of variants observed over
expected. For VPS13D, the probability of LOF intolerance
(pLI) score is 1, virtually certain. Chorea acanthocytosis is
caused in 29 of 31 cases by LOF/LOF mutations in
VPS13A,22 Cohen syndrome in 41 of 45 cases by LOF/
LOF mutations in VPS13B,23–27 and Parkinson disease in
3 of 4 cases by LOF/LOF mutations in VPS13C
cases.28,29 In summary, VPS13D is intolerant to complete
LOF of both alleles, being likely incompatible with life,
consistent with our finding of only compound heterozy-
gous missense/LOF or nonessential splice/LOF mutations.
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Vps13D Disruption in Drosophila Is Lethal
and Causes Mitochondrial Defects
Known also as CG32113 in flies, fly Vps13D shows
33% protein identity to the human gene (see Table 2).
Consistent with Vps13d lethality in mice, flies dis-
rupted for Vps13D do not survive beyond the 2nd
instar larvae stage. This lethality was confirmed with 2
independent lines containing large insertions in the
coding region of Vps13D, including compound hetero-
zygous animals containing 1 copy of each Vps13D
allele, hence ruling out secondary mutations as the
cause of lethality.
While we observed no obvious defects in markers
for Golgi, endoplasmic reticulum, lysosomes, and the
nucleus (data not shown), we observed that deletion of
Vps13D led to severe alterations in mitochondrial mor-
phology. In early 2nd instar larvae before lethality,
instead of forming fine mitochondrial networks in indi-
vidual cells, mitochondria appear as singular, enlarged
objects. This abnormal mitochondrial appearance was
present in the larval brain (see Fig 2A) and other tissues
in these young larvae (not shown).
We then used RNAi-mediated knockdown30 to in-
hibit expression of Vps13D specifically in motoneurons.
This allows for survival of larvae to the 3rd instar stage
(death at pupal stage), which enables further characteriza-
tion of Vps13D’s autonomous function in neurons. By
coexpression of mitoGFP targeted specifically to
TABLE 2. Mutations of VPS13D Paralogs in Animals and Humans
Mutation Intolerance in Humans Human Disorder
Yeast
Cellular
Functions
Implicated
Fruit Fly
Paralogs,
Mutant
Phenotypes
Vertebral
Paralogs
Mouse Null
Phenotypes
RVIS %ExAC
v2 RVIS
LoF O/E LoF pLI Disorder Disease
Mutation
Type
Vps13,17
sporulation,
integrity of
mitochondria,
Golgi
organization,
organelle
junction
Vps13/
CG2093,19
reduced
life span,
neuro-
degeneration
VPS13A
viable,
acanthocytosis,
neurologically
abnormal in
129/SvEv
background20
21.85
(2.03%)
23.75
(0.51%)
30/119.0 0.00 Chorea
acanthocytosis22
1/31 MIS/MIS
1/31 MIS/LOF1
29/31 LOF1/LOF1
VPS13C
viable,
Neurologically
normalc
20.61
(17.5%)
22.83
(1.20%)
83/141.1 0.00 Parkinson
disease28,29
1/4 MIS/LOF1
3/4 LOF1/LOF1
Vps13B/
CG15523,
no data
available
VPS13B
no data available
20.81
(12.08%)
22.13
(2.69%)
65/127.8 0.00 Cohen
syndrome23–27
3/45 MIS/MIS
1/45 MIS/LOF1
41/45 LOF1/LOF1
Vps13D/
CG32113,b
embryonic
lethality,
mitochondrial
defects
VPS13D
embryonic
lethality before
placentation
with complete
penetranced
24.23
(0.14%)
25.77
(0.11%)
28a/156.2 1.00 Ataxia/Spasticityb 5/7 MIS/LOF1
2/7 splice?/LOF1
Residual Variation Intolerance Score (RVIS) is a mutation intolerance score (more negative, more intolerant) and its percentile rank in all human
genes is given in parenthesis (lower, more intolerant). %ExAC v2 RVIS is RVIS v4, constructed on ExAC v2 (gnomAD) release. LoF (Loss of func-
tion) represents stop-gained and essential splice site mutations as defined in ExAC. LoF O/E represents the ratio of the number of variants observed
over expected. LoF pLI is the probability of LoF Intolerance (pLI >50.9 regarded as extremely LoF intolerant). RVIS, LoF O/E and pLI are based
on ExAC. LOF indicates LoF plus frameshift mutations and LOF1 includes large deletions and insertions as well.
aFor VPS13D, gnomAD lists 65 LOF variants, with no increased frequency in any particular geographic/ethnic population.
bThis study.
cMGI2444207.
dMGI2448530.
ExAC5Exome Aggregation Consortium; MIS5missense.
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mitochondria of the RNAi-depleted neurons,15 we
observed enlarged spherical mitochondria (see Fig 2B).
Compared to a control RNAi line targeting luciferase,
knockdown by Vps13D RNAi resulted in a significant
reduction in quantified form factor (see Fig 2C), consis-
tent with a loss of complexity of the mitochondria net-
work coinciding with enlarged, isolated mitochondria.
These observations suggest a role for Vps13D in regulat-
ing mitochondrial morphology and potentially also mito-
chondrial function in neurons.
The abnormal mitochondrial network in neuronal
cell bodies led us to hypothesize that loss of Vps13D
would deleteriously impact the distribution of mitochon-
dria to distal regions of neurons.
Previous studies have linked deficiencies in mito-
chondrial trafficking to distal neurites in neurodegenera-
tive diseases and neuropathies.31,32 We observed that
reduction of Vps13D in motoneurons led to strong
impairment in the distribution of mitochondria in
peripheral axons in segmental nerves and neuromuscular
junction synapses (Fig 3). The density of mitochondria
was progressively reduced concomitant with increased
distance from the cell body locations in the central ner-
vous system. This failure to distribute mitochondria
FIGURE 3: Knockdown of Vps13D in Drosophila motoneurons disrupts the distribution of mitochondria to distal axons. (A) Seg-
mental nerves (horseradish peroxidase [HRP], red) containing motoneuron axons expressing fluorescent mitochondrial marker
mitoGFP (green) of control RNAi and Vps13D RNAi knockdown (RNAi) animals. Nerves near the ventral nerve cord (VNC; prox-
imal, top) and distant from the VNC (distal, bottom) are shown. Scale bar: 10 mm. (B) Quantification of the mitochondrial con-
tent per area within segmental nerves in proximal and distal regions of motoneurons expressing control RNAi (white) versus
Vps13D RNAi (gray). Data are normalized to the control RNAi proximal region condition; n10 individual nerves from 5 differ-
ent animals. Error bars represent standard error; ****p<0.0001 (Student t test). (C) Larval neuromuscular junction (NMJ) synap-
ses from motoneuron axons expressing fluorescent mitochondrial marker mitoGFP (green) of control and Vps13D RNAi
knockdown animals. HRP (red) labels neuronal membrane, whereas DLG (disc large 1, blue) labels NMJ postsynaptic region.
High-magnification images of the synaptic region (indicated by the dashed box) are shown (right panels) to highlight mitochon-
dria occupying the synaptic region. Scale bars: 20mm (left) and 2.5mm (right). (D) Quantification of the mitochondrial content
in the NMJ synapse per area of motoneurons expressing control RNAi (white) versus Vps13D RNAi (gray). Data are normalized
to the control RNAi condition; n55 animals (each n represents the average mitochondrial content of 6 NMJ synapses/ani-
mal). Error bars represent standard error; ****p<0.0001 (Student t test).
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resembles previously described defects for mutations in
mitochondrial fission/fusion machinery.31
Patient-Derived Fibroblasts Show Altered
Mitochondrial Morphology
Given these fly data, we also investigated mitochondrial
function and morphology in human fibroblasts. Staining
fibroblasts from the affected subjects of family UM1 with
MitoTracker, which accumulates in mitochondria in a
membrane potential–dependent manner, revealed signifi-
cantly brighter mitochondria (Fig 4). Whereas the typical
mitochondrial network of elongated objects and branches
was observed in both control and patient cells, the
perinuclear regions of only affected cells often contained
unusually bright and significantly more spherical mitochon-
drial objects, which were mostly in clusters and at higher
magnification appeared to be donut-shaped. To quantify
the abundance of the bright and spherical mitochondria in
each cell line, we extracted the top 1% brightest pixels from
each image and selected circular objects based on computed
circularity score. The average number of such abnormal
mitochondrial objects was 6-fold higher in the affected
compared to control cells. In the perinuclear region, such
objects were identified in clusters (3) in 10% of normal
but 91% and 67% of fibroblasts of affected subjects’ cells.
Consistent with the Drosophila data, form factor analysis
FIGURE 4: Patient fibroblasts Family UM1 contain abnormal spherical mitochondria. (A–D) Comparison of mitochondria in 4
fibroblast lines of Family UM1 stained with MitoTracker. (A) UMCtrl1: wild type for VPS13D. (B) UM1.17: asymptomatic hetero-
zygous carrier of the Gly1190Asp missense mutation. (C, D) UM1.2 and UM1.4: VPS13D compound heterozygous patients.
Note that whereas the majority of the mitochondria in the control cells are elongated and of similar intensity, the patient cells
are loaded with particularly bright, circular mitochondrial objects mostly localized in the perinuclear region. (E) Intensity histo-
gram of MitoTracker images. The x-axis represents the intensity; the numbers of pixels are plotted on the y-axis (the black
plots in natural number scale and the gray plots in log scale). Note that both patients have many more pixels with higher inten-
sity, indicative of the increase in bright MitoTracker-stained objects. (F, G) Perinuclear mitochondria at higher magnification
(603 lens, 43 zoom). Control mitochondria (F; UMCtrl1) are elongated, tubular, and interconnected, whereas the patient mito-
chondria (G; UM1.2) are often donut-shaped. Here, brightness was individually optimized to reveal the structural details and is
not comparable. Scale bars: 20mm (A–D) and 2mm (F, G). (H) Average number of circular mitochondrial (MT) objects identified
by image processing. Such circular objects are present in the control cell lines at low frequencies but become much more abun-
dant in the affected cell lines (6-fold increase). (I) Percentage of cells with at least 3 perinuclear circular MT objects. The
patient fibroblast cultures have a higher number of cells with perinuclear circular MT objects than control (6- and 9-fold
increase). (J) Form factor analysis of the mitochondrial network stained by MitoTracker. In H–J, error bars represent standard
error; *p<1024, **p<1025, and ***p<1026 (Student t test). [Color figure can be viewed at www.annalsofneurology.org]
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also revealed a significant reduction in the degree of mito-
chondrial branching in the affected fibroblasts compared to
controls. These observations suggest structural defects in
mitochondria in VPS13D-deficient fibroblasts.
Independent analysis of fibroblasts of the proband of
family LUB1 demonstrated that the affected fibroblasts
expressed reduced levels of mitochondrial GRP75 protein
compared to controls (Fig 5). Form factor analysis of GRP75
immunostaining revealed a similar reduction in the degree of
mitochondrial branching of proband fibroblasts compared to
2 unrelated healthy controls. These structural mitochondrial
changes were accompanied by a reduced ATP production
rate of LUB1.1 compared to control fibroblasts.
Discussion
In this study, we have identified 7 different compound het-
erozygous mutations in VPS13D in 12 patients and have
linked VPS13D/Vps13D defects in patient fibroblasts and
in flies to mitochondrial deficits. Our study also included a
large family with ataxia (SCAR4) and linkage to a 10Mb
region on chromosome 1p36 harboring the VPS13D gene.
The core phenotype of the 11 patients older than 2
years with compound heterozygous VPS13D mutations is
characterized by movement disorders of the ataxia-spasticity
spectrum, ranging from predominant ataxia, spastic ataxia,
to spastic paraplegia without ataxia, and ataxia plus pheno-
types. The latter included 2 cases with an additional devel-
opmental delay phenotype (NIJ3 and NIJ4). The youngest
patient, WF1 of age 2 years at the last evaluation, presented
with hypotonia and developmental delay, including motor
delay, and was not yet ambulatory. These 3 patients also
have different types of or additional mutations, as NIJ3 and
WF1 carry nonessential splice region variants in addition to
an LOF. This may be more severe than the combination of
missense/LOF found in the other cases. In addition, NIJ4’s
presentation may be complicated by an additional mutation
in OPA1. The protein encoded by OPA1 is also implicated
in mitochondrial function. It is conceivable that there may
be an interactive effect of the 2 mutated genes linked to
mitochondrial dysfunction. Interestingly, recent data have
shown that about 5% of patients carry 2 independent Men-
delian diseases.33 However, digenic inheritance cannot be
ascertained based on this single case. Of note, homozygous
FIGURE 5: Altered mitochondrial morphology and decreased adenosine triphosphate (ATP) in VPS13D mutant fibroblasts of Fam-
ily LUB1. (A) Western blot analysis shows mitochondrial GRP75 protein levels in the VPS13D mutant fibroblasts (LUB1.1), patient’s
parents (LUB1.3 and LUB1.4), and healthy control fibroblasts (LUBCtrl2) with b-actin as loading control. (B) Quantification of the
above GRP75 Western blot using ImageJ. (C) The mitochondrial network was investigated under basal conditions by confocal
microscopy in fixed cells immunostained with anti-GRP75. Scale bar: 20mm. (D) Form factor as a measure for mitochondrial inter-
connectivity (GRP75 immunostaining) was calculated for 2 control fibroblast lines (LUBCtrl1, LUBCrtl2) and 1 patient line (LUB1.1).
Each dot represents measurement in a single cell (n520). The mean values and the standard deviations of the investigated indi-
viduals are shown. (E) ATP production was determined based on luminescence. ATP concentration (micromoles) was calculated
per minute per milligram of protein (n53 independent experiments). In B and E, the error bars indicate the standard error of the
mean of n3 independent experiments. [Color figure can be viewed at www.annalsofneurology.org]
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or compound heterozygous OPA1 mutations cause an
extended multisystem phenotype that includes ataxia and
spastic paraplegia, known as Behr syndrome.34 Although
there was complete coverage of the OPA1 coding regions
and splice sites, no second mutation in the OPA1 gene
was detected by exome nor by copy number analyses
(conducted as described).35 Hence, although we cannot
exclude an undetected intronic or promoter mutation
that is not penetrant, as the father does not have optic
atrophy, we believe Behr syndrome as an alternative diag-
nosis in this case is not likely.
The overlap between genetic forms of ataxias and
hereditary spastic paraplegias is well recognized, as there
are other examples of genes (eg, SPG7) that when
mutated can give rise to either pure ataxia or spastic
paraplegia or to a mixed phenotype of spastic ataxia,36,37
developmental delay, and seizures, and other complex
phenotypes commonly accompany early onset recessive
ataxias.2 In addition, there was variability in age of onset
in our patients, which is also not unusual for ataxias. Fre-
quently observed neurological comorbidities in our series
included peripheral axonal neuropathy and extrapyrami-
dal signs such as myoclonus and dystonia. Infertility was
noted in 2 male cases. Although it is currently uncertain
whether this is VPS13D-related, infertility is a known
feature of mitochondrial disease.38
VPS13D encodes a large protein (4,388 amino acids),
whose paralogs cause other neurological disorders; VPS13A
mutations cause chorea acanthocytosis, characterized by a
severe hyperkinetic movement disorder, myopathy, epileptic
seizures, cognitive decline, and behavioral changes,22,39 and
perturb protein homeostasis in the fly.19 VPS13B is involved
in Cohen syndrome40,41 and VPS13C in rare cases of
genetic Parkinson disease with mitochondrial dysregulation
and mitophagy.28 Most of these disease-associated muta-
tions are LOF/LOF (see Table 2). In contrast to the other
VPS13 paralogs, knocking out VPS13D’s homologs in Dro-
sophila (our results) and mouse (MGI:2448530) leads to
embryonic lethality, and not a single LOF/LOF mutation
was identified, suggesting that some residual VPS13D func-
tion in humans may be critical for survival. In addition, the
ExAC server’s pLI score, that is, the probability that a gene
may be intolerant to haploinsufficiency, for VPS13D is 1, in
contrast to all other VPS13 genes (see Table 2).42 We did
not, however, observe the predicted intolerance to haploin-
sufficiency, as 1 parent of each of the cases reported here
was haploinsufficient, but none was symptomatic, including
1 parent who lived into their 90s without apparent neuro-
logical problems.
Our genetic data allow for some first, yet cautious
speculations on genotype–phenotype correlations. First,
our current data collectively point to missense/LOF
mutations tending to cause relatively pure ataxia and/or
spasticity. Second, as suggested by the more severe NIJ3
and WF1 cases, who carry nonessential splice site/LOF
mutations, other mutation type combinations may be
associated with a broader and/or more severe spectrum of
phenotypes. Lastly, the other severe case, NIJ4, had a
coexistent dominant OPA1 mutation and corresponding
optic atrophy,43 which was also observed in the subject’s
mother. The OPA1 mutation may contribute epistatically
to the phenotype, as OPA1 also affects mitochondrial
function.43
Although our study convincingly establishes mis-
sense/LOF mutations in VPS13D as causing ataxia/spas-
tic paraplegia and mitochondrial pathology, many
questions remain to be addressed. Clinically, predicting
the phenotype from new mutations in VPS13D will be
difficult. Even for missense/LOF mutation carriers, the
clinical presentation varied in our series. In addition,
homozygous or compound heterozygous missense muta-
tions were not observed here. As VPS13D is a large gene
with many missense variants reported in databases in-
cluding homozygosity,42 it will be even more difficult to
predict pathogenicity of any novel biallelic missense
variants.
Although further work is warranted to pin down
the precise mitochondrial defect, we have shown abnor-
mal mitochondrial morphology in both flies and patient
cell lines, and reduced mitochondrial function in fibro-
blasts. Mitochondrial dysfunction is associated with sev-
eral other ataxias and spastic paraplegias such as
Friedreich ataxia,44 SCA28,45 POLG,46 and SPG7,47 as
well as in some unexplained ataxias.48 Although we
observed a defect in mitochondrial distribution in both
Drosophila neurons lacking Vps13D and patient fibro-
blasts containing mutations in VPS13D, the precise bio-
logical underpinnings of this defect are still under
investigation, including electron microscopy studies to
assess mitochondrial morphology. Alterations of mito-
chondrial dynamics such as transport, fission, and/or
fusion31 can all potentially manifest in aberrant distribu-
tion of mitochondria throughout the cell. Various muta-
tions in mitochondrial genes lead to the production of
reactive oxygen species,49 which can additionally disrupt
mitochondrial distribution in neurons. Combining the in
vitro cellular model of patient fibroblasts and neurons
differentiated from induced pluripotent stem cells with
in vivo experiments in the genetic fly model may help us
parse out the cellular role of VPS13D in mitochondrial
biology and disease progression. These methods will also
allow for testing of potential therapies that target mito-
chondrial dysfunction and that could be common to
other forms of ataxia and spastic paraplegias.
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While this article was under review, Anding et al
published findings showing VPS13D to be a ubiquitin-
binding protein affecting mitochondrial fission and
fusion,50 consistent with our findings, and also imple-
mented VPS13D in autophagy, a process that we have
recently reported to be involved in ataxia.51
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